Printer Friendly

FDA ADVISORY PANEL TO CONSIDER MEDTRONIC TRANSVENE LEADS AT MEETING IN AUGUST

 MINNEAPOLIS, July 7 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT), said today that the company had been informed that its Transvene(TM) lead system designed for use in implanting the PCD(R) device without major surgery will be reviewed at the U.S. Food and Drug Administration's Circulatory Systems Advisory Panel meeting on Aug. 2, 1993.
 FDA panels, comprised of physicians and other specialists knowledgeable about medical or technical issues related to drugs or devices under consideration, advise the agency as it processes applications for subsequent commercial approval.
 The Transvene lead system, which has been in clinical trials since March, 1990, is implanted through the vascular system to deliver anti- tachyarrhythmia therapies from the PCD to the lower chamber of the heart. Lead systems currently cleared in the United States for the PCD are attached to the outer surface of the heart during open-chest surgery.
 The Transvene lead system has been approved for sales outside the United States since November, 1991. Most implants of the PCD devices outside the United States now employ the Transvene lead system, which has reduced cost and patient trauma significantly.
 Medtronic, Inc., headquartered in Minneapolis, is the world's leading therapeutic medical device company.
 -0- 7/7/93
 /CONTACT: Dale Beumer, Investor Relations, 612-574-3038, or Dick Reid, Public Relations, 612-574-3052, both of Medtronic/
 (MDT)


CO: Medtronic, Inc. ST: Minnesota IN: MTC SU: PDT

AL -- MN004 -- 9217 07/07/93 17:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 7, 1993
Words:234
Previous Article:ARGONAUT GROUP ANNOUNCES SECOND QUARTER EARNINGS
Next Article:REXALL SUNDOWN ANNOUNCES THIRD QUARTER RESULTS
Topics:


Related Articles
PCD LEAD SYSTEM REQUIRING NO MAJOR CHEST SURGERY IS RELEASED BY MEDTRONIC IN EUROPE
FDA ADVISORY PANEL TO CONSIDER MEDTRONIC PCD DEVICE AT FEBRUARY MEETING
MEDTRONIC, VENTRITEX ANNOUNCE AGREEMENT TO CROSS-LICENSE TACHYARRHYTHMIA PATENTS
FDA ADVISORY PANEL RECOMMENDS APPROVAL OF LESS-INVASIVE LEADS FOR PCD SYSTEM
MEDTRONIC POSTS SOLID GAIN IN FIRST-QUARTER EARNINGS AS NEWER BUSINESSES CONTINUE GROWTH
MEDTRONIC ANNOUNCES EXPANSION OF CLINICAL IMPLANTS OF NEW TRANSVENOUS LEAD SYSTEM
MEDTRONIC REPORTS REGULATORY ACTION ON TRANSVENE LEAD SYSTEM
FDA ADVISORY PANEL RECOMMENDS APPROVAL OF MEDTRONIC RF CARDIAC ABLATION SYSTEM
FORMER EMPI, MEDTRONIC REGULATORY PERSON JOINS ANGEION AS VICE PRESIDENT, REGULATORY AND CLINICAL AFFAIRS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters